Lilly will obtain exclusive rights to sell treatments discovered using InSilico’s Pharma.AI model.

Pediatric EBGLYSS trial meets endpoints in dermatitis care; Broader immunology portfolio gains attention beyond metabolic ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Eli Lilly (LLY) rated Sell/Avoid: overvaluation, slowing GLP-1 growth, Novo competition, bearish technicals and insider selling. Click here to read more.

Shares of Eli Lilly & Co. LLY slid 2.09% to $878.24 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.67% to 6,368.85 and Dow ...

Wall Street and healthcare stocks sank as Eli Lilly was downgraded, Novo’s Wegovy HD won FDA approval, and drug supply risks rose.

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Eli Lilly and Company (NYSE: LLY) is a titan of the pharmaceutical industry, a position bolstered by the monumental success ...

The pharmaceutical sector is highly competitive and driven by innovation. GLP-1 weight loss drugs are a perfect example. Novo Nordisk was first to market with a GLP-1 shot. Eli Lilly's GLP-1 shots ...